Staidson (Beijing) BioPharmaceuticals Co., Ltd. announced a private placement of not more than 142,607,266 A shares for gross proceeds of not more than CNY 580.000.000 on December 22, 2022. The transaction will include participation from not more than 35 investors. The shares issued cannot be transferred within 6 months from the date of completion of this issuance. The transaction has been approved at the 14th meeting of the fifth board of directors and the 14th meeting of the fifth board of supervisors of the company. The transaction still needs to be approved by the company's general meeting of shareholders, the Shenzhen Stock Exchange, and the China Securities Regulatory Commission.

On March 6, 2023, the company announced that the application for the issuance of the shares has been accepted by the Shenzhen Stock Exchange.